Breakthrough in Cancer Research: Coupling IL-2 with IL-10 to Enhance Anti-Tumor Immunity

Strategic Insights -

Researchers at Deka Biosciences Inc. have made a significant discovery in cancer treatment, coupling IL-2 with IL-10 to mitigate toxicity and enhance anti-tumor immunity. According to the study, published in Cell Reports Medicine, this combination prevents toxicity while retaining cytotoxic T cell activation and limiting regulatory T cell expansion. The research, led by Steven Dudics and Julie J. Ahn, suggests that this innovative approach elicits a balanced and pleiotropic anti-tumor immune response.

Key Takeaways:

  • The study found that coupling IL-2 with IL-10 prevents toxicity and enhances anti-tumor immunity in human primary cells, mouse models, and non-human primates.
  • The IL-2/IL-10 fusion molecule, targeted to EGFR via an anti-EGFR single-chain variable fragment (scFV), potently activates T cells and natural killer (NK) cells and elicits interferon (IFN)g-dependent anti-tumor function.
  • The research suggests that combining IL-2 with IL-10 uncouples toxicity from immune activation, leading to a balanced and pleiotropic anti-tumor immune response.
  • The study was conducted using human primary cells, mouse models, and non-human primates, demonstrating the potential of this approach for cancer treatment.
  • The IL-2/IL-10 fusion molecule, known as DK2, was developed by Deka Biosciences Inc. and has shown promise in elicitating anti-tumor function without peripheral inflammatory toxicity or Treg accumulation.

Statistics:

  • The study included human primary cells, mouse models, and non-human primates in its research design.
  • The IL-2/IL-10 fusion molecule, DK2, was found to potently activate T cells and NK cells, eliciting IFNg-dependent anti-tumor function.
  • The research indicates that the combination of IL-2 with IL-10 prevents toxicity while retaining cytotoxic T cell activation and limiting Treg expansion.
  • The study was published in Cell Reports Medicine, a peer-reviewed journal published by Cell Press.

Sources:

  • Coupling IL-2 with IL-10 to mitigate toxicity and enhance antitumor immunity. Cell Reports Medicine, 2025;6(8):102257. Cell Reports Medicine can be contacted at: Cell Press, 50 Hampshire St, Floor 5, Cambridge, MA 02139, USA.
  • Findings on Receptor Protein-Tyrosine Kinases Discussed by Steven Dudics and Co-Researchers (Coupling IL-2 with IL-10 to mitigate toxicity and enhance antitumor immunity). Life Science Weekly. September 16, 2025; p 1628.